Successfully developed China's 1st fast-acting human insulin analog - Prandilin^® (Lispro)

Successfully developed China's 1st long-acting human insulin analog - Basalin^® (Glargine)

Successfully developed China's 1st premixed human insulin analog - Prandilin ^® 25 (Lispro 25R)

Company was restructured and renamed to“Gan & Lee Pharmaceuticals Co., Ltd.”

Patents were obtained for the Molecular Chaperone Technology in China and PCT patent was obtained in the US

Received production approval and GMP certificate for Basalin^® from the NMPA (before CFDA)

Basalin^® went on sale

Basalin^® entered the international market, including Egypt, Pakistan, Mexico, etc.

The company's sales revenue exceeded RMB100 million

China's 1st independently developed insulin injection pen-Insulin Pen was launched

The company completed the shareholding transformation and its name was changed to “Gan & Lee Pharmaceuticals”

China's 1st premixed human insulin analog Prandilin^® 25 was launched

Founded Gan & Lee Pharmaceuticals USA

Completed the construction of the new insulin analog manufacturing plant in Beijing

Insulin glargine was allowed by the FDA to proceed with Phase I clinical study in US

Basalin passed Europe's QP inspection and was allowed to proceed with Phase I and Phase III clinical trials in Europe

Gan & Lee attended the 78th American Diabetes Annual Conference (ADA) as the first Chinese pharmaceuticals to attend the conference

Gan & Lee concluded a commercialization and supply agreement with Sandoz, a subsidiary of Novartis on biosimilar versions of insulins used in patients with type 1 and type 2 diabetes

Recombinant insulin lispro was allowed by the FDA & European Medicines Agency to proceed with Phase I and Phase III clinical trials in the US and Europe

Gan & Lee was Initially listed on the A-share index on the Shanghai Stock Exchange

Aspart was approved for listing in China

Started the construction of Gan & Lee Linyi Production Base

Phase 1 Drug Candidate GLR2007 has been Granted Orphan Drug Designation and Fast Track Designation by the US FDA

Gan & Lee Announces New Partnership with the International Diabetes Federation

EMA granted orphan drug designation for GLR2007

Mixed Protamine Human Insulin Injection (30R) from Gan & Lee Pharmaceuticals is listed

GZR18, a GLP-1 RA, began the phase I clinical trial in China and the US.